2. Zogenix (ZGNX - Get Report), a specialty pharmaceutical company, has two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Its two products are SUMAVEL DosePro, its first commercial product, and its lead product candidate ZX002.
Net loss for the first quarter 2011 is forecasted to come in at $17.4 million or 50 cents per share, according to analysts polled by Bloomberg. Sales for the quarter are seen at $9.8 million as compared to $8.80 in the fourth quarter of 2010. Gross margin for the quarter is likely to come in at 52.1% as against 44.8% in 2010 first quarter.
All the four analysts covering the stock recommend a buy rating on it. There are no sell ratings on the stock. Analysts polled by Bloomberg expect the stock to gain an average 128.3% to $10.0 in value from current levels.